65-47-4

Basic information

• Product Name: CTP
• Synonyms: 5’-ctp;cytidine,5’-(tetrahydrogentriphosphate);cytidine3’-triphosphate;cytidine5’-(tetrahydrogentriphosphate);cytidine5’-triphosphoricacid;cytidinetriphosphate;CYTIDINE 5'-TRIPHOSPHATE;CTP
• CAS NO: 65-47-4
• Molecular Formula: C₉H₁₆N₃O₁₄P₃
• Molecular Weight: 483.16
• EINECS: 200-611-4
• Product Categories: Pharmaceutical Intermediates;Nucleic acids
• Mol File: 65-47-4.mol
• Article Data: 16

Chemical Properties

• Appearance: white powder
• Storage Temp.: 2-8°C
• CAS DataBase Reference: CTP(CAS DataBase Reference)
• NIST Chemistry Reference: CTP(65-47-4)
• EPA Substance Registry System: CTP(65-47-4)

Safety Data

• Hazardous Substances Data: 65-47-4(Hazardous Substances Data)

Usage

General Description

Cytidine-5'-triphosphate (CTP) is a nucleoside triphosphate that consists of a cytosine base linked to a ribose sugar and three phosphate groups. It is involved in various biochemical processes as a precursor for the synthesis of RNA. CTP is an essential building block for the formation of nucleic acids and is essential for the replication and transcription of genetic material. It also serves as a substrate for various enzymes involved in the biosynthesis of complex molecules such as phospholipids and glycoproteins. Additionally, CTP plays a critical role in cellular signaling and energy transfer processes.

Upstream product

• 63-37-6 cytidine monophosphate 
• 63-39-8 UTP 
• 65-46-3 CYTIDINE 
• 63-38-7 cytidine diphosphate 
• 56-65-5 ATP 
• 56-65-5 β-L-adenosine-5'-triphospate 
• 4105-38-8 Tri-O-acetyluridine 
• 58-96-8 uridine 
• 56787-28-1 2',3',5'-tri-O-acetylcytidine 
• 82913-19-7 [(2R,3R,4R)-3,4-diacetoxy-5-[2-oxo-4-(1,2,4-triazol-1-yl)pyrimidin-1-yl]tetrahydrofuran-2-yl]methyl acetate 

Downstream Products

• 63-38-7 cytidine diphosphate 
• 83008-69-9 adenosine(cytidine) 5',5'''-P¹,P⁴-tetraphosphate 
• 65-46-3 CYTIDINE 
• 263016-94-0 4-diphosphocytidyl-2-C-methylerythritol 
• 98300-80-2 2-O-(cytidin-5'-yloxyphosphoryl)-5-(2-hydroxy-acetamido)-3,5-dideoxy-β-D-glycero-D-galacto-2-nonulopyranosonic acid 
• 84651-07-0 C₂'p5'C₂'p5'C 
• 16511-83-4 C₂'p5'C 
• 1170694-62-8 C₂'p5'A₂'p5'C 
• 97226-64-7 A₂'p5'A₂'p5'C 
• 97205-06-6 A₂'p5'A₂'p5'U 
• 1270047-38-5 C₂'p5'A₂'p5'A 
• 1270047-39-6 A₂'p5'A₂'p5'A₂'p5'C 
• 10061-10-6 uridylyl-(5'->2')-adenosine 
• 10318-62-4 adenylyl(2'-5')cytidine 

Relevant articles and documents

Synthetic method of nucleoside tetraphosphate

The invention discloses a synthetic method of nucleoside tetraphosphate. The synthetic method comprises the steps of carrying out selective phosphorylation reaction by virtue of nucleoside and a cyclic phosphorylation reagent, and carrying out oxidation and hydrolysis loop opening, so as to obtain nucleoside tetraphosphate. The structure of the cyclic phosphorylation reagent is represented by a formula I (shown in the description). According to the synthetic method, 5'-nucleoside tetraphosphate is selectively generated from nucleoside under the effect of the high-selectivity phosphorylation reagent, and 3'-OH (and 2'-OH) does not need to be protected in the process, namely that the generaiton of 3'(and 2'-)tetraphosphate can be effectively inhibited. Nucleoside tetraphosphate synthesized by virtue of the method has wide use ranges in the biology fields of DNA sequencing, labeling, extension and the like; currently, the selling prices is expensive, a synthetic method is complex, the reaction selectivity is poor; and the synthetic method provided by the invention is good in selectivity and easy in separation and purification, required experimental conditions are simple, and the synthetic processes are all conventional chemical reactions, so that the synthetic method is applicable to large-scale popularization and use.

Nucleotide promiscuity of 3-phosphoglycerate kinase is in focus: Implications for the design of better anti-HIV analogues

The wide specificity of 3-phosphoglycerate kinase (PGK) towards its nucleotide substrate is a property that allows contribution of this enzyme to the effective phosphorylation (i.e. activation) of nucleotide-based pro-drugs against HIV. Here, the structural basis of the nucleotide-PGK interaction is characterised in comparison to other kinases, namely pyruvate kinase (PK) and creatine kinase (CK), by enzyme kinetic analysis and structural modelling (docking) studies. The results provided evidence for favouring the purine vs. pyrimidine base containing nucleotides for PGK rather than for PK or CK. This is due to the exceptional ability of PGK in forming the hydrophobic contacts of the nucleotide rings that assures the appropriate positioning of the connected phosphate-chain for catalysis. As for the d-/l-configurations of the nucleotides, the l-forms (both purine and pyrimidine) are well accepted by PGK rather than either by PK or CK. Here again the dominance of the hydrophobic interactions of the l-form of pyrimidines with PGK is underlined in comparison with those of PK or CK. Furthermore, for the l-forms, the absence of the ribose OH-groups with PGK is better tolerated for the purine than for the pyrimidine containing compounds. On the other hand, the positioning of the phosphate-chain is an even more important term for PGK in the case of both purines and pyrimidines with an l-configuration, as deduced from the present kinetic studies with various nucleotide-site mutants of PGK. These characteristics of the kinase-nucleotide interactions can provide a guideline for designing new drugs.

Substrate specificity of T5 bacteriophage deoxyribonucleoside monophosphate kinase and its application for the synthesis of [α-32P]d/rNTP

Bacteriophage T5 deoxynucleoside monophosphate kinase (dNMP kinase, EC 2.7.4.13) is shown to catalyze the phosphorylation of both d2CMP and ribonucleotides AMP, GMP, and CMP, but does not phosphorylate UMP. For natural acceptors of the phosphoryl group, k m and k cat were found. The applicability of T5 dNMP kinase as a universal enzyme capable of the phosphorylation of labelled r/dNMP was shown for the synthesis of [α- 32P]rNTP and [α-32P]dNTP.